Skip to main navigation Skip to search Skip to main content

AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis

  • Seung Taek Lee
  • , Ha Eun Kim
  • , So Yeon Kim
  • , Jong Yeong Lee
  • , Kyung-Hwa Nam
  • , Sang Hyun Kim
  • , Jun Young Park
  • , Jin Kyeong Choi*
  • *Corresponding author for this work
  • Jeonbuk National University
  • Kyungpook National University
  • Chungbuk National University

Research output: Contribution to journal › Journal article › peer-review

Abstract

Background: Atopic dermatitis (AD) is characterized by dysregulated immune responses and persistent inflammation. Regulatory B (Breg) cells suppress inflammation, but the metabolic mechanisms constraining their function in AD remain unclear. Objective: We sought to define whether immunometabolic regulation governs Breg cell differentiation and function in AD. Methods: Mouse and human B cells were stimulated with the adenosine monophosphate–activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) under inflammatory conditions, with genetic and pharmacologic perturbations. Functional and mechanistic analyses were performed with coculture systems, a 2,4-dinitrochlorobenzene and Dermatophagoides farinae extract–induced murine model of AD, adoptive transfer approaches, adoptive transfer, and human peripheral blood mononuclear cells from patients with AD. Results: AICAR treatment or adoptive transfer of AICAR-induced Breg cells significantly attenuated AD-like inflammation, whereas AMPK inhibition or IL-10 blockade abrogated these effects. Mechanistically, AICAR induced IL-10–producing Breg cells through AMPK-dependent suppression of mTOR signaling and mitochondrial reactive oxygen species while preserving oxidative phosphorylation. This reprogramming selectively enhanced regulatory B-cell function and suppressed STAT1 signaling without affecting STAT3. Functionally, these Breg cells suppressed TH1, TH2, and TH17 responses in an IL-10–dependent manner without expanding Foxp3+ regulatory T cells. In human peripheral blood mononuclear cells from patients with AD, AICAR restored immunometabolic coupling by increasing IL-10–producing B cells and reducing proinflammatory cytokine production. Conclusion: These findings identify an AMPK-mTOR-redox metabolic checkpoint that governs regulatory B-cell function and restrains AD inflammation, linking metabolic control to immune regulation.

Original languageEnglish
JournalJournal of Allergy and Clinical Immunology
DOIs
StateAccepted/In press - 2026

Keywords

  • AMPK
  • Atopic dermatitis
  • B-cell regulation
  • IL-10
  • immunometabolism
  • inflammation
  • metabolic reprogramming
  • mitochondrial reactive oxygen species
  • mTOR
  • regulatory B cells

Fingerprint

Dive into the research topics of 'AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis'. Together they form a unique fingerprint.

Cite this